RMTG (Regenerative Medical Technology Group) EBIT: $0.82 Mil (TTM As of Mar. 2026)


What is Regenerative Medical Technology Group EBIT?

Regenerative Medical Technology Group RMTG +0.44% EBIT is $0.82 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Regenerative Medical Technology Group's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $1.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.82 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Regenerative Medical Technology Group's annualized ROC % for the quarter that ended in Mar. 2026 was 3.95%. Regenerative Medical Technology Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 329.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Regenerative Medical Technology Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.06%.

Regenerative Medical Technology Group  (OTCPK:RMTG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Regenerative Medical Technology Group's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=0.92 * ( 1 - 0% )/( (23.183 + 23.424)/ 2 )
=0.92/23.3035
=3.95 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.489 - 16.908 - ( 0.957 - max(0, 36.825 - 1.223+0.957))
=23.183

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.01 - 18.225 - ( 1.061 - max(0, 38.205 - 1.566+1.061))
=23.424

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Regenerative Medical Technology Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5.256/( ( (1.492 + max(-19.4, 0)) + (1.694 + max(-19.547, 0)) )/ 2 )
=5.256/( ( 1.492 + 1.694 )/ 2 )
=5.256/1.593
=329.94 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.044 + 0.159 + 0.063) - (16.908 + 0.351 + 2.407)
=-19.4

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.035 + 0.298 + 0.172) - (18.225 + 0.505 + 1.322)
=-19.547

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Regenerative Medical Technology Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=0.816/20.113
=4.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group EBIT Related Terms

Regenerative Medical Technology Group EBIT Historical Data

* Premium members only.

The historical data trend for Regenerative Medical Technology Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group EBIT Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -10.15 -1.17 -3.32 0.08 -0.37

Regenerative Medical Technology Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 -0.25 -0.86 0.62 1.31

RMTG vs WINT, LIPO, CYTOF: EBIT Comparison

For the Biotechnology subindustry, Regenerative Medical Technology Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerative Medical Technology Group EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Regenerative Medical Technology Group's EV-to-EBIT falls into.


Regenerative Medical Technology Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $0.82 Mil mean?
Regenerative Medical Technology Group (RMTG) has a EBIT of $0.82 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Regenerative Medical Technology Group.
Is Regenerative Medical Technology Group's EBIT too high?
Regenerative Medical Technology Group's current EBIT is $0.82 Mil.
How does Regenerative Medical Technology Group's EBIT compare to WINT and LIPO?
Regenerative Medical Technology Group's EBIT of $0.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Regenerative Medical Technology Group. Regenerative Medical Technology Group's current EBIT is $0.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.06, compared to a current price of $0.05 — trading 24.7% below its estimated fair value. The current EBIT is $0.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current EBIT is $0.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.